COST-EFFECTIVENESS OF DOLUTEGRAVIR, A NEW GENERATION INTEGRASE INHIBITOR, IN HIV-1 TREATMENT EXPERIENCED PATIENTS IN FRANCE

被引：0
|
作者：
Despiegel, N. [1 ]
Marcellin, A. G. [2 ]
Aubin, C. [3 ]
Espinas, C. [1 ]
Laurisse, A. [4 ]
Pialoux, G. [5 ]
机构：
[1] Optum, Nanterre, France
[2] Hop La Pitie Salpetriere, AP HP, Paris, France
[3] GlaxoSmithKline, Marly Le Roi, France
[4] ViiV Healthcare France, Marly Le Roi, France
[5] Hop Tenon, AP HP, F-75970 Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2526
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN85
引用
收藏
页码：A678 / A679
页数：3
相关论文
共 50 条
  • [41] Raltegravir (MK-0518): An integrase inhibitor for the treatment of HIV-1
    Evering, Teresa Hope
    Markowitz, Martin
    DRUGS OF TODAY, 2007, 43 (12) : 865 - 877
  • [42] NEW INTEGRASE STRAND TRANSFER INHIBITOR APPROVED TO TREAT HIV-1
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2013, 113 (12) : 22 - 22
  • [43] A COST-EFFECTIVENESS EVALUATION FOR A NEW THERAPY IN HIV TREATMENT
    Malhan, S.
    Kockaya, G.
    Zengin, Elbir T.
    Dalgic, C.
    Yenilmez, F. B.
    Cerci, P.
    Oksuz, E.
    Tayfun, K.
    Unal, S.
    VALUE IN HEALTH, 2014, 17 (07) : A677 - A677
  • [44] Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naive and pretreated patients
    Saladini, F.
    Meini, G.
    Bianco, C.
    Monno, L.
    Punzi, G.
    Pecorari, M.
    Borghi, V.
    Di Pietro, M.
    Filice, G.
    Gismondo, M. R.
    Micheli, V.
    Penco, G.
    Carli, T.
    De Luca, A.
    Zazzi, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (10) : E428 - E430
  • [45] COST-EFFECTIVENESS OF SINGLE VERSUS MULTIPLE TABLET REGIMENS FOR TREATMENT OF HIV-1 INFECTION
    Sweet, D. E.
    Zhuo, D. Y.
    Macalalad, A. R.
    Signorovitch, J.
    VALUE IN HEALTH, 2014, 17 (03) : A274 - A274
  • [46] Dolutegravir: A new integrase strand transfer inhibitor for the treatment of HIV (vol 34, pg 506, 2014)
    Shah, Bhavik M.
    PHARMACOTHERAPY, 2014, 34 (06): : 648 - 648
  • [47] The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults
    Underwood, Mark R.
    Johns, Brian A.
    Sato, Akihiko
    Martin, Jeffrey N.
    Deeks, Steven G.
    Fujiwara, Tamio
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 61 (03) : 297 - 301
  • [48] HIV-1 Integrase Resistance among Highly Antiretroviral Experienced Patients from Morocco
    Alaoui, Najwa
    El Alaoui, Moulay Abdelaziz
    El Annaz, Hicham
    Farissi, Fatima Zahra
    Alaoui, Amine Sanaa
    El Fahime, Elmostapha
    Mrani, Saad
    INTERVIROLOGY, 2019, 62 (02) : 65 - 71
  • [49] Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
    Suarez-Garcia, Ines
    Alejos, Belen
    Hernando, Victoria
    Vinuela, Laura
    Vera Garcia, Mar
    Rial-Crestelo, David
    Perez Elias, Maria Jesus
    Albendin Iglesias, Helena
    Peraire, Joaquim
    Tiraboschi, Juan
    Diaz, Asuncion
    Moreno, Santiago
    Jarrin, Inma
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (06) : 1423 - 1432
  • [50] Cost effectiveness of tipranavir in treatment-experienced HIV patients in the USA
    Simpson, KN
    Chumney, ECG
    Hicks, CB
    Finnern, H
    VALUE IN HEALTH, 2006, 9 (03) : A156 - A156
12345